Trastuzumab (Herceptin) and lapatinib, two approved therapies for HER2-positive breast cancers (HER2+ BCs), have significantly improved the outcomes for HER2+ BC patients and have opened up an era of cancer treatment in this disease via targeted therapy [2, 3]. This evidence concerns the gene ERBB2 and breast carcinoma.